Furthermore, impacts on the tumor immune surveillance, such as co-inhibitory signaling pathway interaction (PD-1/PD-L1 and CTLA-4/CD86) and tumoral immunological balances (such as CD28: B7 binding versus CTLA-4: B7 binding), would be explored to make a more comprehensive exploration for the antitumor activity of ESG. Here, CTLA4 is linked to neoplasm.